Alnylam identifies who's getting ax

Alnylam Pharmaceuticals ($ALNY) has detailed plans for laying off 52 workers, part of a broad effort to slash its RNA workforce 33%. The Boston Business Journal reports that the biotech told state officials it is axing its senior director of biotherapeutics, a senior director of business development, a senior director of pharma operations and a senior director of information technology. The Journal reports that "nine senior scientists and 14 research associates positions will also be eliminated." Story

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.